Age: 77.0
Sex: F
Vaccine: VARZOS
Symptoms: Blood pressure systolic increased, Injection site erythema, Injection site pain, Injection site rash, Mobility decreased
Clinical narrative: Redness at the injection site; Pain at the injection site; Rash at the injection site; Difficulty raising arm; Platelet count dropped to 116; Systolic pressure over 200; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 77-year-old female patient who received Herpes zoster (Shingrix) (batch number DP2X9, expiry date unknown) for prophylaxis.   Concurrent medical conditions included immune thrombocytopenia and platelet count abnormal. Concomitant products included rituximab (Rituxan).   On 14th October 2022, the patient received the 1st dose of Shingrix. In November 2022, less than a month after receiving Shingrix, the patient experienced platelet count decreased and blood pressure systolic increased. On an unknown date, the patient experienced injection site erythema, injection site pain, injection site rash and mobility decreased. On an unknown date, the outcome of the injection site erythema, injection site pain and injection site rash were recovered/resolved and the outcome of the mobility decreased was unknown and the outcome of the platelet count decreased and blood pressure systolic increased were not recovered/not resolved.   It was unknown if the reporter considered the injection site erythema, injection site pain, injection site rash and mobility decreased to be related to Shingrix. The reporter considered the platelet count decreased and blood pressure systolic increased to be related to Shingrix.   Additional Information: GSK Receipt Date: 10-NOV-2022 Reporter's Comment: The reporter was was the patient.  The reporter reported receiving Shingrix, in the left arm.  The reporter reported that, having Immune Thrombocytopenia, which affected their platelet count.  The reporter reported having a platelet treatment with Rituxan on 13th September 2022 and being told the effects of the Rituxan lasts approximately 6 months and they should be ok to proceed with Shingrix dose by hematologist's assistant, despite hematologist advising patient not to receive vaccinations.  The reporter reported that, the platelet count was 241 after last treatment with Rituxan.  The reporter reported that, having platelet count checked last week and being advised their platelet count had dropped to 116, which was unusual for them so soon after Rituxan treatment.  The reporter reported that, systolic pressure was over 200, which was associated with the drop in platelet count.  The reporter reported that, belief drop in platelet count was due to receipt of Shingrix dose, as it had been over 2 and a half years since they experienced such a drop in their platelet count.  Th reporter also reported experiencing pain, redness, and a rash at the injection site.  The reporter reported experiencing difficulty raising their arm, due to the pain from the injection.  The reporter reported platelet count and blood pressure had yet to return to normal.  The reporter reported pain, redness, and rash at injection site had resolved. The reporter consented to follow up.